The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here are three stocks where Wall Street’s estimates seem disconnected from reality and some better opportunities to consider.
Carter's (CRI)
Consensus Price Target: $42.67 (28.3% implied return)
Rumored to sell more than 10 products for every child born in the United States, Carter's (NYSE: CRI) is an American designer and marketer of children's apparel.
Why Are We Bearish on CRI?
- Poor same-store sales performance over the past two years indicates it’s having trouble bringing new shoppers into its stores
- Low free cash flow margin of 7.5% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
Carter’s stock price of $33.26 implies a valuation ratio of 9.7x forward P/E. Read our free research report to see why you should think twice about including CRI in your portfolio.
Transcat (TRNS)
Consensus Price Target: $104.33 (22.1% implied return)
Serving the pharmaceutical, industrial manufacturing, energy, and chemical process industries, Transcat (NASDAQ: TRNS) provides measurement instruments and supplies.
Why Does TRNS Worry Us?
- Issuance of new shares over the last two years caused its earnings per share to fall by 15.9% annually while its revenue grew
- Low returns on capital reflect management’s struggle to allocate funds effectively, and its shrinking returns suggest its past profit sources are losing steam
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Transcat is trading at $85.48 per share, or 43.3x forward P/E. To fully understand why you should be careful with TRNS, check out our full research report (it’s free).
Quanex (NX)
Consensus Price Target: $27.25 (19% implied return)
Starting in the seamless tube industry, Quanex (NYSE: NX) manufactures building products like window, door, kitchen, and bath cabinet components.
Why Are We Out on NX?
- Estimated sales growth of 1.3% for the next 12 months implies demand will slow from its two-year trend
- Performance over the past two years shows its incremental sales were much less profitable, as its earnings per share fell by 14.1% annually
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
At $22.89 per share, Quanex trades at 11.4x forward P/E. If you’re considering NX for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
